Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Neuro-Oncology
Published in: Journal of Neuro-Oncology 3/2012

01-12-2012 | Clinical Study

Re-irradiation in recurrent malignant glioma: prognostic value of [18F]FET–PET

Authors: Maximilian Niyazi, Nathalie Jansen, Ute Ganswindt, Silke Birgit Schwarz, Julia Geisler, Oliver Schnell, Karen Büsing, Sabina Eigenbrod, Christian la Fougère, Claus Belka

Published in: Journal of Neuro-Oncology | Issue 3/2012

Login to get access

Abstract

The aim of the present study is to determine new positron emission tomography (PET) imaging-related factors predictive of progression-free survival as well as survival in patients with recurrent malignant glioma (MG) prior to and after re-irradiation. Fifty-six patients with recurrent MG who underwent re-irradiation treatment and pretherapeutic dynamic [18F]-fluoroethyl-l-tyrosine (FET)–PET scan were retrospectively analyzed. The prognostic value of different parameters, such as biological tumor volume, maximal tumor uptake (SUVmax/BG), mean tumor uptake (SUVmean/BG), as well as uptake kinetics, was evaluated. [18F]FET uptake kinetics was classified according to a five-point rating as category G1–2 (strongly/mainly increasing kinetics), G3 (mixed 1:1), or G4–5 (mainly/strongly decreasing kinetics). Patients within the pretherapeutic kinetic group G4–5 had significantly worse survival than the other two groups (p = 0.01). Multivariate analysis revealed that histologic grade, Karnofsky Performance Score (KPS), and kinetic group were independent significant predictors for survival after re-irradiation. The uptake kinetics of [18F]FET–PET is an independent determinant of overall and to a lesser extent also progression-free survival. Thus, [18F]FET–PET kinetics may provide valuable additional prognostic information for treatment decisions.
Literature
1.
Minniti G, Amelio D, Amichetti M, Salvati M, Muni R, Bozzao A, Lanzetta G, Scarpino S, Arcella A, Enrici RM (2010) Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 97:377–381PubMedCrossRef
2.
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466PubMedCrossRef
3.
Ernst-Stecken A, Ganslandt O, Lambrecht U, Sauer R, Grabenbauer G (2007) Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma. J Neurooncol 81:287–294PubMedCrossRef
4.
Niyazi M, Siefert A, Schwarz SB, Ganswindt U, Kreth FW, Tonn JC, Belka C (2011) Therapeutic options for recurrent malignant glioma. Radiother Oncol 98:1–14PubMedCrossRef
5.
Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26:4189–4199PubMedCrossRef
6.
Metellus P, Colin C, Taieb D, Guedj E, Nanni-Metellus I, de Paula AM, Colavolpe C, Fuentes S, Dufour H, Barrie M, Chinot O, Ouafik L, Figarella-Branger D (2011) IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. J Neurooncol 105:591–600PubMedCrossRef
7.
Gambhir SS (2002) Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2:683–693PubMedCrossRef
8.
Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, Christian B, Ruppert J, Bernstein T, Kraus G, Mantil JC (2003) Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 64:227–237PubMedCrossRef
9.
Charnley N, West CM, Barnett CM, Brock C, Bydder GM, Glaser M, Newlands ES, Swindell R, Matthews J, Price P (2006) Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. Int J Radiat Oncol Biol Phys 66:331–338PubMedCrossRef
10.
Niyazi M, Geisler J, Siefert A, Schwarz SB, Ganswindt U, Garny S, Schnell O, Suchorska B, Kreth FW, Tonn JC, Bartenstein P, la Fougere C, Belka C (2011) FET–PET for malignant glioma treatment planning. Radiother Oncol 99:44–48PubMedCrossRef
11.
Piroth MD, Pinkawa M, Holy R, Stoffels G, Demirel C, Attieh C, Kaiser HJ, Langen KJ, Eble MJ (2009) Integrated-boost IMRT or 3-D-CRT using FET–PET based auto-contoured target volume delineation for glioblastoma multiforme–a dosimetric comparison. Radiat Oncol 4:57PubMedCrossRef
12.
Wyss M, Hofer S, Bruehlmeier M, Hefti M, Uhlmann C, Bartschi E, Buettner UW, Roelcke U (2009) Early metabolic responses in temozolomide treated low-grade glioma patients. J Neurooncol 95:87–93PubMedCrossRef
13.
Popperl G, Gotz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K (2004) Value of O-(2-[18F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 31:1464–1470PubMedCrossRef
14.
la Fougere C, Suchorska B, Bartenstein P, Kreth FW, Tonn JC (2011) Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol 13:806–819PubMedCrossRef
15.
Piroth MD, Holy R, Pinkawa M, Stoffels G, Kaiser HJ, Galldiks N, Herzog H, Coenen HH, Eble MJ, Langen KJ (2011) Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. Radiother Oncol 99:218–224PubMedCrossRef
16.
Piroth MD, Pinkawa M, Holy R, Klotz J, Nussen S, Stoffels G, Coenen HH, Kaiser HJ, Langen KJ, Eble MJ (2011) Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 80:176–184PubMedCrossRef
17.
Floeth FW, Pauleit D, Sabel M, Stoffels G, Reifenberger G, Riemenschneider MJ, Jansen P, Coenen HH, Steiger HJ, Langen KJ (2007) Prognostic value of O-(2–18F-fluoroethyl)-l-tyrosine PET and MRI in low-grade glioma. J Nucl Med 48:519–527PubMedCrossRef
18.
Niyazi M, Ganswindt U, Schwarz SB, Kreth FW, Tonn JC, Geisler J, la Fougère C, Ertl L, Linn J, Siefert A, Belka C (2012) Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys. 82:67–76
19.
Galldiks N, Langen KJ, Holy R, Pinkawa M, Stoffels G, Nolte KW, Kaiser HJ, Filss CP, Fink GR, Coenen HH, Eble MJ, Piroth MD (2012) Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-l-tyrosine PET in comparison to MRI. J Nucl Med 53:1048–1057PubMedCrossRef
20.
Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553–563PubMed
Metadata
Title
Re-irradiation in recurrent malignant glioma: prognostic value of [18F]FET–PET
Authors
Maximilian Niyazi
Nathalie Jansen
Ute Ganswindt
Silke Birgit Schwarz
Julia Geisler
Oliver Schnell
Karen Büsing
Sabina Eigenbrod
Christian la Fougère
Claus Belka
Publication date
01-12-2012
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 3/2012
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-012-0980-7

Other articles of this Issue 3/2012

Journal of Neuro-Oncology 3/2012 Go to the issue

Clinical Study

Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional status

Laboratory Investigation

HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment

Laboratory Investigation

Growth properties of SF188/V+ human glioma in rats in vivo observed by magnetic resonance imaging

Laboratory Investigation

The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas

Clinical Study

Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery

Laboratory Investigation

Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment